147

therapeutic
published patents

56

oncology
published patents

310

research tools

46

diagnostic
published patents

Our Technology Offers

Welcome to our Technology Offers website

You want access to an innovative offer which is based on the excellence of Inserm, the leading academic research and clinical institute dedicated to human health in Europe? Find out our technologies offers of patents and research tools: here is a sample of our patents.

Microbiota dependent spontaneous colorectal cancer

100% of the animals spontaneously tumor in the distal part of the colon after 7 month of age, or within 5 weeks after bone marrow transfer. The […]

Tagged leptin receptors hek293t cells

Hek293T cells were transfected with short form human leptin receptors (OBR) tagged individually with either Rluc (pIRESpuro3, Clontech) or YFP […]

Human ferroportin polyclonal antibodies

Rabbit Polyclonal antibodies raised against 3 differents portions of the iron exporter Human Ferroportin 1 = Solute Carrier Family 40 (Iron-Regulated […]

Apoa2 humanized transgenic mouse – line delta

The mice are hemizygous for the human apolipoprotein A2 (ApoA2) gene expressed under the control of the homologous promoter (-911/+2045). They are […]

Apoa2 humanized transgenic mouse – line beta

The mice are hemizygous for the human apolipoprotein A2 (ApoA2) gene expressed under the control of the homologous promoter (-911/+2045). They are […]

Apoa2 humanized transgenic mouse – line lambda

The mice are hemizygous for the human apolipoprotein A2 (ApoA2) gene expressed under the control of the homologous promoter (-911/+2045). They are […]

Xenograft models to study stem and chemoresistant cells, and to assess

We have recently contributed to establish a robust xenotransplantation model (NSG, NRG) to study the leukemic engraftment as well as the stem cell […]

More posts

You might also be interested in